Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valens Company Inc (The) Ordinary Shares VLNCF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
The Valens Co Inc is a developer and manufacturer of cannabinoid-based products. The company's extraction methods are CO2, ethanol, hydrocarbon, solvent-less, and terpene extraction. Its products are Tinctures, Capsules, Beverages, and Vape cartridges among others. Its reportable segments are Cannabis operations, Analytical testing, and Corporate. The company has a business presence in Canada and other countries, and it generates a majority of revenue from the Cannabis operations segment.


OTCQX:VLNCF - Post by User

Valens Company Inc (The) Ordinary Shares
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Nov 22, 2022 7:01am
271 Views
Post# 35117949

New Press Release - BOTH LEADING INDEPENDENT PROXY ADVISORS RECOMMEND SHAREHOLDERS OF THE VALENS COMPANY INC. VOTE FOR THE PROPOSED ARRANGEMENT WITH SNDL INC.

New Press Release - BOTH LEADING INDEPENDENT PROXY ADVISORS RECOMMEND SHAREHOLDERS OF THE VALENS COMPANY INC. VOTE FOR THE PROPOSED ARRANGEMENT WITH SNDL INC.
ISS highlights that "the arrangement is expected to produce upwards of $15 million of additional EBITDA on an annual run-rate basis through synergies and other strategic initiatives" and that "shareholder approval of arrangement resolution is warranted"Glass Lewis cites the strategic rationale as...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities